Publications by authors named "R W Hankins"

Hydrogen selenide (HSe) is an emerging biomolecule of interest with similar properties to that of other gaseous signaling molecules (i.e., gasotransmitters that include nitric oxide, carbon monoxide, and hydrogen sulfide).

View Article and Find Full Text PDF
Article Synopsis
  • Cefazolin is the preferred antibiotic for preventing surgical site infections (SSIs), but prescribing can be affected by patient-reported penicillin allergies.
  • In April 2022, Nebraska Medicine adjusted electronic medical record alerts to reduce unnecessary restrictions on prescribing cefazolin for patients with non-severe penicillin allergies.
  • A study found that following this change, the use of cefazolin in patients with documented penicillin allergies rose significantly, with no increase in adverse reactions or complications.
View Article and Find Full Text PDF

Introduction/background: Phosphatase and tensin homolog (PTEN) genomic deletions and transmembrane protease, serine 2/v-ets avian erthyroblastosis virus E26 oncogene homolog (ERG) rearrangements are two of the most common genetic abnormalities associated with prostate cancer. Prior studies have demonstrated these alterations portend worse clinical outcomes. Our objective is to evaluate the impact of biopsy-determined PTEN losses and TMPRSS2-ERG fusion on biochemical progression-free survival (bPFS) and overall survival (OS) in patients who receive SBRT for localized prostate cancer.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines the laboratory monitoring frequency for adverse events related to outpatient parenteral antimicrobial therapy (OPAT) during treatments with cefazolin and ceftriaxone.
  • It found an occurrence rate of 2.7 OPAT-related adverse events per 1000 sets of weekly lab tests.
  • This suggests that less frequent lab monitoring could be both safe and acceptable for patients receiving these therapies.
View Article and Find Full Text PDF

Purpose: Intensity-modulated radiation therapy (IMRT) with brachytherapy boost for unfavorable prostate cancer has been shown to improve biochemical relapse-free survival compared to IMRT alone. Stereotactic body radiation therapy (SBRT) is a less-invasive alternative to brachytherapy. Early outcomes utilizing SBRT boost suggest low rates of high-grade toxicity with a maintained patient-reported quality of life.

View Article and Find Full Text PDF